| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99284 |
Emergency department visit for the evaluation and management, high severity |
97,865 |
81,877 |
$13.93M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
49,091 |
43,306 |
$7.09M |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
30,683 |
24,453 |
$1.96M |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
36,736 |
29,627 |
$1.51M |
| 71045 |
Radiologic examination, chest; single view |
9,316 |
7,783 |
$1.39M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
6,324 |
5,325 |
$931K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
1,535 |
1,246 |
$601K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
16,915 |
13,073 |
$599K |
| 43235 |
|
364 |
318 |
$593K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
79,018 |
64,735 |
$355K |
| 71046 |
Radiologic examination, chest; 2 views |
4,190 |
3,431 |
$338K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
2,208 |
1,625 |
$336K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
4,491 |
3,899 |
$327K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
1,486 |
1,429 |
$297K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
3,592 |
3,167 |
$233K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
46,815 |
37,776 |
$223K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
2,781 |
2,461 |
$216K |
| 74018 |
|
1,099 |
1,000 |
$204K |
| 70450 |
Computed tomography, head or brain; without contrast material |
1,657 |
1,329 |
$180K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
2,036 |
635 |
$178K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
10,014 |
7,552 |
$131K |
| 36415 |
Collection of venous blood by venipuncture |
50,701 |
42,102 |
$129K |
| 81025 |
|
20,089 |
16,954 |
$101K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
130 |
50 |
$85K |
| 97165 |
|
569 |
494 |
$83K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
1,485 |
1,428 |
$79K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
3,469 |
3,060 |
$75K |
| 99218 |
|
171 |
120 |
$66K |
| 99217 |
|
185 |
136 |
$61K |
| 59025 |
Fetal non-stress test |
169 |
133 |
$55K |
| 84484 |
|
7,397 |
5,580 |
$51K |
| 97162 |
|
289 |
257 |
$42K |
| 80053 |
Comprehensive metabolic panel |
5,747 |
4,679 |
$38K |
| 92523 |
|
247 |
220 |
$37K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
8,643 |
6,971 |
$37K |
| 81001 |
|
20,100 |
16,374 |
$37K |
| G0378 |
Hospital observation service, per hour |
267 |
105 |
$35K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
717 |
400 |
$33K |
| 43770 |
|
26 |
15 |
$32K |
| 83690 |
|
8,894 |
7,265 |
$30K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
777 |
731 |
$29K |
| 80076 |
|
5,296 |
4,306 |
$26K |
| 87088 |
|
3,783 |
3,085 |
$16K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
400 |
371 |
$16K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
222 |
201 |
$15K |
| 74246 |
|
82 |
69 |
$15K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
291 |
224 |
$13K |
| 99221 |
|
26 |
24 |
$13K |
| 77066 |
Tomosynthesis, mammo |
44 |
39 |
$13K |
| 99239 |
Hospital discharge day management, more than 30 minutes |
40 |
38 |
$11K |
| 74220 |
|
98 |
77 |
$11K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
81 |
77 |
$9K |
| 97161 |
|
57 |
55 |
$9K |
| 76642 |
|
54 |
54 |
$8K |
| 99224 |
|
134 |
37 |
$6K |
| 80047 |
|
1,352 |
1,086 |
$5K |
| 77065 |
Tomosynthesis, mammo |
19 |
17 |
$5K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
375 |
160 |
$3K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
23 |
14 |
$3K |
| 97163 |
|
16 |
12 |
$2K |
| 87634 |
|
31 |
27 |
$2K |
| 85027 |
|
514 |
330 |
$2K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
209 |
170 |
$1K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
28 |
25 |
$1K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
27 |
24 |
$651.46 |
| 82553 |
|
505 |
296 |
$593.49 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
55 |
36 |
$524.28 |
| 96376 |
|
293 |
81 |
$430.92 |
| 97803 |
|
15 |
12 |
$409.82 |
| 87641 |
|
26 |
25 |
$386.01 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
57 |
37 |
$330.61 |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
156 |
129 |
$277.37 |
| 83880 |
|
17 |
14 |
$274.82 |
| 94760 |
|
13 |
12 |
$218.22 |
| 85014 |
|
223 |
170 |
$208.01 |
| 85379 |
|
27 |
25 |
$195.85 |
| 84443 |
Thyroid stimulating hormone (TSH) |
22 |
14 |
$184.80 |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
17 |
12 |
$149.34 |
| 80061 |
Lipid panel |
21 |
13 |
$139.48 |
| 81003 |
|
105 |
93 |
$138.13 |
| 82565 |
|
51 |
31 |
$121.88 |
| 84439 |
|
21 |
13 |
$90.20 |
| 82570 |
|
15 |
13 |
$56.98 |
| 84550 |
|
20 |
12 |
$45.20 |
| 84156 |
|
18 |
13 |
$44.04 |
| J2795 |
Injection, ropivacaine hydrochloride, 1 mg |
24 |
13 |
$36.80 |
| 85610 |
|
12 |
12 |
$23.80 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
2,080 |
1,574 |
$22.20 |
| 86850 |
|
15 |
12 |
$20.20 |
| 86900 |
|
15 |
12 |
$12.88 |
| 86901 |
|
15 |
12 |
$12.88 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
1,337 |
935 |
$0.00 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
80 |
51 |
$0.00 |
| G0279 |
Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) |
80 |
75 |
$0.00 |
| J2272 |
Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg |
16 |
12 |
$0.00 |
| 97802 |
|
149 |
140 |
$0.00 |
| J2704 |
Injection, propofol, 10 mg |
303 |
144 |
$0.00 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
29 |
26 |
$0.00 |
| J0330 |
Injection, succinylcholine chloride, up to 20 mg |
22 |
12 |
$0.00 |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
86 |
37 |
$0.00 |
| 64488 |
|
18 |
12 |
$0.00 |
| C1889 |
Implantable/insertable device, not otherwise classified |
26 |
15 |
$0.00 |